Eric A. Hughes - Mar 3, 2023 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role: Executive Vice President, Global R&D and Chief Medical Officer
Signature: /s/ Dov Bergwerk as attorney-in-fact for Eric A. Hughes
Stock symbol: TEVA
Transactions as of: Mar 3, 2023
Transactions value $: $0
Form type: 4
Date filed: 3/7/2023, 03:07 PM
Previous filing: Aug 3, 2022
Next filing: Aug 3, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TEVA	Restricted Share Units	Award	$0	+99.6K		$0.00	99.6K	Mar 3, 2023	Ordinary Shares	99.6K		Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F2	Restricted share units were granted on March 3, 2023, with 24,900 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 24,901 vesting on March 3, 2027.
F3	The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Remarks:

Executive Vice President, Global R&D and Chief Medical Officer